EZH2 and cancer: The panel of human CRC organoids tested in our study shows a large variability in response to treatment with the EZH2 inhibitor GSK126, providing a rationale for using high-specificity EZH2 inhibitors as anti-cancer therapy for a subset of CRC patients.